Skip to content

Food and Drug Regulations

C.R.C., c. 870

In forceCurrent to September 30, 2026 HistoryMade under: Food and Drugs Act

Loading…

Part C — Drugs › Division 10 — Access to Drugs in Exceptional Circumstances

Drugs for an Urgent Public Health Need

Amended on June 17, 2026

  •  (1) The following definitions apply in this section and in section C.10.002.

    foreign regulatory authority

    foreign regulatory authority means a government agency or other entity outside Canada that has a legal right to control the manufacturing, use or sale of drugs within its jurisdiction. (autorité réglementaire étrangère)

    public health official

    public health official means

    • (a) the Chief Public Health Officer appointed under subsection 6(1) of the Public Health Agency of Canada Act;

    • (b) the Chief Medical Officer of Health, or equivalent, of a province;

    • (c) the Surgeon General of the Canadian Armed Forces; or

    • (d) the Chief Medical Officer of Public Health for the Department of Indigenous Services. (responsable de la santé publique)

  • (2) Despite sections A.01.040 and C.01.004.1, any person who holds an establishment licence that authorizes the importation of a drug may import a drug for which a notice of compliance has not been issued under section C.08.004 or C.08.004.01, or for which a drug identification number has not been assigned under subsection C.01.014.2(1), if the following conditions are met:

    • (a) a public health official has, within the past year, notified the Minister in writing of

      • (i) an urgent public health need for the immediate use of the drug within their jurisdiction, and

      • (ii) the intended use or purpose of the drug;

    • (b) the drug is authorized by a foreign regulatory authority in the United States, the United Kingdom, Switzerland or the European Union to be sold for the same use or purpose as that described under subparagraph (a)(ii);

    • (c) the drug is in the same category as the category for which the licence was issued;

    • (d) the drug is imported directly from the country in which it is authorized to be sold by the foreign regulatory authority; and

    • (e) the drug is one for which the following information is set out in the List of Drugs for an Urgent Public Health Need that is published by the Government of Canada on its website, as amended from time to time:

      • (i) brand name,

      • (ii) medicinal ingredients,

      • (iii) dosage form,

      • (iv) strength,

      • (v) route of administration, and

      • (vi) identifying code or number, if any, assigned in the country in which the drug was authorized for sale.

  • (3) Sections C.01A.006 and C.01A.007 do not apply in respect of the importation of a drug under subsection (2).

  • (4) For greater certainty, a licensee may, despite subsection C.01A.004(1), import a drug under subsection (2) without having their licence amended under section C.01A.006.

  • (5) Divisions 2 to 4, other than the following provisions, do not apply to the importation of a drug under subsection (2):

  • SOR/2017-133, s. 2
  • SOR/2023-18, s. 2
  • SOR/2024-238, s. 39
  • SOR/2026-96, s. 13
.
  •  (1) A sale of a drug that is imported under subsection C.10.001(2) is exempt from the provisions of these Regulations only if the drug is sold to a person within the jurisdiction of a public health official who has notified the Minister as described in paragraph C.10.001(2)(a), for use in respect of the same urgent public health need for which it was imported.

  • (2) Any person who wholesales such a drug must hold an establishment licence to wholesale a drug in the same category and despite subsection (1), the following provisions apply in respect of the wholesale:

  • SOR/2017-133, s. 2
  • SOR/2022-197, s. 10
  • SOR/2023-247, s. 7
  • SOR/2024-238, s. 40
.

 Every licensee who imports a drug under subsection C.10.001(2) must notify the Minister within 15 days after the day on which it is imported by providing the following information:

  • (a) the name, title and contact information of the person who imported the drug;

  • (b) the brand name of the drug;

  • (c) the medicinal ingredients, strength, dosage form and route of administration of the drug and any identifying code or number assigned to it in the country in which it was authorized for sale;

  • (d) the name of the country from which the drug was imported; and

  • (e) the total quantity of the drug imported.

  • SOR/2017-133, s. 2
  • SOR/2023-18, s. 3
.

Drugs for Exceptional Importation and Sale

Amended on June 17, 2026

  •  (1) The following definitions apply in this section and in sections C.10.005 to C.10.013.

    business day

    business day means a day other than

    • (a) a Saturday; or

    • (b) a Sunday or other holiday. (jour ouvrable)

    designated drug

    designated drug means

    • (a) a drug that is set out in Part 1 of the List of Drugs for Exceptional Importation and Sale; and

    • (b) a lot or batch of a drug that is set out in Part 2 of that list. (drogue désignée)

    drug

    drug[Repealed, SOR/2026-96, s. 15]

    foreign regulatory authority

    foreign regulatory authority has the same meaning as in subsection C.10.001(1). (autorité réglementaire étrangère)

    List of Drugs for Exceptional Importation and Sale

    List of Drugs for Exceptional Importation and Sale means the List of Drugs for Exceptional Importation and Sale that is published by the Government of Canada on its website, as amended from time to time. (Liste des drogues destinées aux importations et aux ventes exceptionnelles)

  • (2) In sections C.10.005 to C.10.013, batch certificate, fabricate, import, MRA country, package/label, recognized building and wholesaler have the same meanings as in subsection C.01A.001(1).

  • (3) In this section and sections C.10.006 and C.10.009,

    • (a) specifications has the same meaning as in section C.02.002; and

    • (b) a reference to specifications is a reference to the specifications with which the designated drug is required to comply within the jurisdiction of the foreign regulatory authority referred to in paragraph C.10.006(1)(b).

  • (4) The definition expiration date in subsection C.01.001(1) does not apply in respect of a designated drug referred to in subsection C.10.007.4(1).

  • SOR/2021-199, s. 5
  • SOR/2026-96, s. 15
.

Amended on June 17, 2026

  •  (1) Subject to subsection (3), the Minister may add a drug that is fabricated outside Canada to Subpart 1 or 2 of Part 1 of the List of Drugs for Exceptional Importation and Sale only if

    • (a) either of the following conditions is met in respect of another drug:

      • (i) the Minister has reasonable grounds to believe that there is a shortage or risk of shortage of the other drug for which a drug identification number has been assigned under subsection C.01.014.2(1) and not been cancelled, or

      • (ii) the sale of the other drug was discontinued;

    • (b) the Minister has reasonable grounds to believe that

      • (i) a shortage of the other drug if it were to occur, or the discontinuation of sale of it could present a risk of injury to human health,

      • (ii) the drug to be added to that list can be substituted for the other drug, and

      • (iii) the drug to be added to that list is authorized to be sold by a foreign regulatory authority within its jurisdiction; and

    • (c) in the case referred to in subparagraph (a)(ii), the drug to be added to that list is added on or before the day that is 36 months after the day on which the sale of the other drug was discontinued.

  • (2) Subject to subsection (3), the Minister may add a lot or batch of a drug that is fabricated in Canada to Subpart 1 or 2 of Part 2 of the List of Drugs for Exceptional Importation and Sale only if

    • (a) either of the following conditions is met in respect of another drug:

      • (i) the Minister has reasonable grounds to believe that there is a shortage or risk of shortage of the other drug for which a drug identification number has been assigned under subsection C.01.014.2(1) and not been cancelled, or

      • (ii) the sale of the other drug was discontinued; and

    • (b) the Minister has reasonable grounds to believe that

      • (i) a shortage of the other drug, if it were to occur, or the discontinuation of sale of it could present a risk of injury to human health, and

      • (ii) the lot or batch of the drug to be added to that list meets the following conditions:

        • (A) it can be substituted for the other drug,

        • (B) it is authorized to be sold by a foreign regulatory authority within its jurisdiction,

        • (C) it is fabricated for consumption or use outside Canada, and

        • (D) despite clause (C), it is no longer intended for export.

  • (3) The Minister may add a drug to Subpart 2 of Part 1 of the List of Drugs for Exceptional Importation and Sale — or a lot or batch of a drug to Subpart 2 of Part 2 of that list — only if

    • (a) the drug is for human use;

    • (b) the drug is not one of the following drugs:

      • (i) a drug included in Schedule I, II, III, IV or V to the Controlled Drugs and Substances Act,

      • (ii) a prescription drug,

      • (iii) a drug listed in Schedule C or D to the Act, or

      • (iv) a drug that is permitted to be sold without a prescription but that is to be administered only under the supervision of a practitioner; and

    • (c) the Minister has reasonable grounds to believe that use of the drug can cause injury to human health or present a risk to public health and the injury or risk can be mitigated by the supervision of a practitioner or pharmacist.

  • SOR/2021-199, s. 5
  • SOR/2026-96, s. 16
.

Amended on June 17, 2026

 For greater certainty, if a lot or batch of a drug is set out in Part 1 or 2 of the List of Drugs for Exceptional Importation and Sale, sections C.10.006 to C.10.013 apply only in respect of that lot or batch.

  • SOR/2026-96, s. 16
.

Amended on June 17, 2026

  •  (1) Despite sections A.01.040 and C.01.004.1, a person who holds an establishment licence that authorizes the importation of a drug may import a designated drug set out in Part 1 of the List of Drugs for Exceptional Importation and Sale if the following conditions are met:

    • (a) the licensee provides the Minister, in the form and manner specified by the Minister and not later than three business days before the day on which the drug is imported, with a notification that contains the following information:

      • (i) the licensee’s name and contact information,

      • (ii) the name and contact information of each fabricator, packager/labeller and tester of the drug and the address of each building in which it is fabricated, packaged/labelled or tested,

      • (iii) in respect of the drug,

        • (A) its brand name,

        • (B) its medicinal ingredients,

        • (C) its dosage form,

        • (D) its strength,

        • (E) its route of administration,

        • (F) its identifying code or number, if any, assigned in the country in which it is authorized for sale, and

        • (G) a detailed description of its conditions of use,

      • (iv) the intended port of entry into Canada,

      • (v) the estimated date of arrival of the shipment of the drug, and

      • (vi) the total quantity of the drug that is intended to be imported on the date referred to in subparagraph (v);

    • (b) the licensee provides the Minister with an attestation, signed and dated by an individual who has authority to bind the licensee, that confirms that the licensee possesses or has immediate access to the specifications for the drug;

    • (c) the drug is in the same category as the category for which the establishment licence was issued;

    • (d) the following information in respect of the drug is set out in Part 1 of the List of Drugs for Exceptional Importation and Sale:

      • (i) the licensee’s name,

      • (ii) the information referred to in clauses (a)(iii)(A) to (F),

      • (iii) the name of the foreign regulatory authority referred to in subparagraph C.10.005(1)(b)(iii),

      • (iv) the maximum limit for the total quantity of the drug that the licensee may import, if applicable,

      • (v) the date after which the drug may no longer be imported, if applicable, and

      • (vi) the lot or batch number of the drug, if applicable;

    • (e) [Repealed, SOR/2026-96, s. 17]

    • (f) the total quantity of the drug that the licensee imports does not exceed the maximum limit referred to in subparagraph (d)(iv), if applicable;

    • (g) the drug is imported on or before the date referred to in subparagraph (d)(v), if applicable; and

    • (h) the licensee has prepared a plan that specifies the measures to be taken in order for the licensee to comply with section C.10.011.

  • (2) [Repealed, SOR/2026-96, s. 17]

  • SOR/2021-199, s. 5
  • SOR/2026-96, s. 17
  • SOR/2026-96, s. 25
.

Amended on June 17, 2026

  •  (1) Despite sections C.01.003, C.01.014 and C.08.002 and subject to subsections (3), (4) and (6), a person who holds an establishment licence may sell a designated drug that is set out in Part 2 of the List of Drugs for Exceptional Importation and Sale for consumption or use in Canada if the conditions set out in subsection (2) are met and, as the case may be,

    • (a) they are the distributor of the drug for consumption or use outside Canada; or

    • (b) they are a wholesaler of a drug.

  • (2) The conditions are the following:

    • (a) the licensee provides the Minister, in the form and manner specified by the Minister and not later than three business days before the day on which the licensee first sells the designated drug for consumption or use in Canada, with a notification that contains the following information:

      • (i) the licensee’s name and contact information,

      • (ii) the name and contact information of each fabricator, packager/labeller and tester of the drug and the address of each building in which it is fabricated, packaged/labelled or tested, and

      • (iii) in respect of the drug,

        • (A) its brand name,

        • (B) its medicinal ingredients,

        • (C) its dosage form,

        • (D) its strength,

        • (E) its route of administration,

        • (F) its identifying code or number, if any, assigned in the country in which it is authorized for sale, and

        • (G) a detailed description of its conditions of use;

    • (b) if the licensee meets the condition set out in paragraph (1)(b) and the designated drug is referred to in any of paragraphs (a), (c) or (d) of the definition wholesaler in subsection C.01A.001(1), the drug is in the same category as the category for which the establishment licence was issued;

    • (c) the following information in respect of the designated drug is set out in Part 2 of the List of Drugs for Exceptional Importation and Sale:

      • (i) the licensee’s name,

      • (ii) the information referred to in clauses (a)(iii)(A) to (F),

      • (iii) the name of the foreign regulatory authority referred to in clause C.10.005(2)(b)(ii)(B),

      • (iv) the maximum limit on the total quantity of the drug that the licensee may sell, if applicable,

      • (v) the date after which the licensee is no longer permitted to sell the drug, if applicable, and

      • (vi) the lot or batch number of the drug;

    • (d) the licensee ensures that the information referred to in clause (a)(iii)(G) is available in English and French and in a manner that permits the safe use of the designated drug; and

    • (e) the licensee has prepared a plan that specifies the measures to be taken in order for them to comply with paragraph (d).

  • (3) The licensee shall not sell, in total, the designated drug in a quantity that exceeds the maximum limit referred to in subparagraph (2)(c)(iv), if applicable.

  • (4) The licensee shall not sell the designated drug after the date referred to in subparagraph (2)(c)(v), if applicable.

  • (5) The licensee shall ensure that the information referred to in clause (2)(a)(iii)(G) is available in accordance with paragraph (2)(d) until at least the latest expiration date of the designated drug that they sold.

  • (6) This section does not apply — in respect of a designated drug sold by the licensee under subsection (1) — to another person who holds an establishment licence and sells the drug.

    SOR/2026-96, s. 18
.

Amended on June 17, 2026

 Despite sections C.01.003, C.01.014 and C.08.002, the fabricator of a designated drug who is neither the distributor of the drug for consumption or use outside Canada nor a wholesaler of the drug may sell the drug for consumption or use in Canada only to that distributor or such a wholesaler.

  • SOR/2026-96, s. 18
.

Amended on June 17, 2026

  •  (1) Subject to subsection (3) and sections C.10.007.3, C.10.009, C.10.010 and C.10.010.2, a sale of a designated drug is exempt from the following provisions:

    • (a) sections A.01.014 to A.01.017 and A.01.051; and

    • (b) the provisions of Part C other than

      • (i) sections C.01.016, C.01.017, C.01.019 to C.01.020.1 and C.01.040.3 to C.01.051.1,

      • (ii) the provisions of Divisions 1A and 2, and

      • (iii) sections C.10.007.1 to C.10.013.

  • (2) For greater certainty, for the purposes of section C.01.016, the manufacturer of a designated drug is required to comply only with the requirements set out in sections C.01.017 and C.01.019 in respect of the drug.

  • (3) Subsections (1) and (2) cease to apply in respect of the sale of a designated drug on its expiration date.

  • SOR/2021-199, s. 5
  • SOR/2026-96, s. 19
.

Amended on June 17, 2026

  •  (1) This section applies — but paragraph C.02.018(3)(c) and section C.02.019 do not apply — to a person who holds an establishment licence in respect of a designated drug that they import under section C.10.006.

  • (2) The licensee shall perform the finished product testing on a sample of the designated drug that is taken either

    • (a) after receipt of each lot or batch of the designated drug on their premises in Canada; or

    • (b) before receipt of each lot or batch of the designated drug on their premises in Canada if the following conditions are met:

      • (i) the licensee has evidence that the Minister considers satisfactory, in the interests of the health of the consumer or purchaser, to demonstrate that lots or batches of the designated drug sold to them by the vendor of the lot or batch are consistently manufactured in accordance with and consistently comply with the specifications for that drug,

      • (i.1) the licensee undertakes periodic complete confirmatory testing, with a frequency that the Minister considers satisfactory, in the interests of the health of the consumer or purchaser, and

      • (ii) the designated drug has not been transported or stored under conditions that may affect its compliance with the specifications for that drug.

  • (3) The licensee shall possess or have immediate access to the specifications for the designated drug until at least the latest expiration date of the designated drug.

  • (4) If the licensee receives on their premises in Canada a lot or batch of a designated drug whose useful life is more than 30 days, they shall visually inspect the lot or batch to confirm the identity of the product.

  • (5) Subsections (2) and (4) do not apply to the licensee if the designated drug is fabricated, packaged/labelled and tested in an MRA country at a recognized building and the following conditions are met:

    • (a) the address of the building is set out in their establishment licence; and

    • (b) they retain a copy of the batch certificate for each lot or batch of the designated drug that they receive for at least one year after the expiration date of the lot or batch.

  • (6) [Repealed, SOR/2026-96, s. 20]

  • SOR/2021-199, s. 5
  • SOR/2026-96, s. 20
.

Amended on June 17, 2026

  •  (1) A person who holds an establishment license and who imports a designated drug under section C.10.006 is required to comply with paragraphs C.02.020(1)(a), (b) and (d) in respect of the drug but is not required to maintain the records referred to in those paragraphs on their premises in Canada.

  • (2) The Minister may request that the licensee provide to the Minister any of the records referred to in paragraphs C.02.020(1)(a), (b) or (d) in respect of the designated drug.

  • (3) The licensee shall provide the requested records in the time, form and manner specified by the Minister.

  • SOR/2021-199, s. 5
  • SOR/2026-96, s. 21
.

Amended on June 17, 2026

 A person who holds an establishment licence and imports a designated drug under section C.10.006 — or a person who holds an establishment licence and sells a designated drug under subsection C.10.007.1(1) and is not the manufacturer of the drug — shall submit to the Minister, in the form and manner specified by the Minister, a report of all information relating to the following serious adverse drug reactions within 15 days after the day on which they receive or become aware of the information, whichever occurs first:

  • (a) any serious adverse drug reaction that has occurred in Canada with respect to the drug; and

  • (b) any serious unexpected adverse drug reaction that has occurred outside Canada with respect to the drug.

    SOR/2026-96, s. 22
.

Amended on June 17, 2026

  •  (1) Despite subsection C.01.050(4), section C.01.050 applies — in respect of a designated drug — to a person who holds an establishment licence and imports the drug under section C.10.006 or a person who holds an establishment licence and sells the drug under subsection C.10.007.1(1), with any necessary modifications.

  • (2) A reference to a foreign regulatory authority in the applicable paragraph of subsection C.01.050(2) includes a reference to the foreign regulatory authority referred to in subparagraph C.10.006(1)(d)(iii) or C.10.007.1(2)(c)(iii), as the case may be, if that foreign regulatory authority is not set out in any of Parts A to C of the List of Foreign Regulatory Authorities for the Purposes of Section C.01.050 of the Food and Drug Regulations, published by the Government of Canada on its website, as amended from time to time.

  • SOR/2026-96, s. 22
.

Amended on June 17, 2026

 A drug that is removed from the List of Drugs for Exceptional Importation and Sale before the date referred to in subsection C.10.011(2) continues to be considered a designated drug for the purposes of sections C.10.010.1, C.10.010.2 and C.10.011 until that date.

  • SOR/2026-96, s. 22
.

Amended on June 17, 2026

  •  (1) No person shall sell on a retail basis a designated drug that is set out in Subpart 1 of Part 1 or 2 of the List of Drugs for Exceptional Importation and Sale unless the information referred to in clause C.10.006(1)(a)(iii)(G) is available in English and French to the purchaser or consumer in any of the following manners:

    • (a) the information accompanies the drug;

    • (b) the information is provided in writing to the purchaser or consumer at the time of sale;

    • (c) in the case where the drug is accessible to the public for self-selection, copies of the information are placed adjacent to the drug in a manner that permits the purchaser or consumer to take one.

  • (2) For the purposes of subsection (1), the English and French versions of the information referred to in clause C.10.006(1)(a)(iii)(G) need not be available in the same manner.

  • (3) Subsection (1) does not apply to the sale of a designated drug that is set out in Subpart 1 of Part 1 or 2 of the List of Drugs for Exceptional Importation and Sale by a pharmacist under a prescription, or by a practitioner.

  • SOR/2026-96, s. 22
.

Amended on June 17, 2026

  •  (1) A person who holds an establishment licence shall not sell a designated drug that they imported under section C.10.006 unless they ensure that the information referred to in clause C.10.006(1)(a)(iii)(G) is available in English and French and in a manner that permits the safe use of the drug.

  • (2) The licensee shall ensure that the information is available in accordance with subsection (1) until at least the latest expiration date of the designated drug that they imported.

  • SOR/2021-199, s. 5
  • SOR/2026-96, s. 23
.

Amended on June 17, 2026

 A person who holds an establishment licence in respect of a drug shall not sell a designated drug set out in Subpart 2 of Part 1 or 2 of the List of Drugs for Exceptional Importation and Sale except to a practitioner, a pharmacist, a hospital as defined in subsection C.01.020.1(4) or another person who holds an establishment licence in respect of a drug.

    SOR/2026-96, s. 24
.

Amended on June 17, 2026

 A pharmacist or a person working under a pharmacist’s supervision shall not sell a designated drug set out in Subpart 2 of Part 1 or 2 of the List of Drugs for Exceptional Importation and Sale on a retail basis unless the drug is not accessible to the public for self-selection.

  • SOR/2026-96, s. 24
.

Extended Expiration Dates

Amended on June 17, 2026

 The following definitions apply in this section and in sections C.10.015 to C.10.021.

extended expiration date

extended expiration date means, in respect of a specified lot or batch, the date set out in column 2 of the List of Drugs with Extended Expiration Dates. (date limite d’utilisation reportée)

List of Drugs with Extended Expiration Dates

List of Drugs with Extended Expiration Dates means the List of Drugs with Extended Expiration Dates that is published by the Government of Canada on its website, as amended from time to time. (Liste des drogues dont la date limite d’utilisation est reportée)

specified lot or batch

specified lot or batch means a lot or batch of a drug set out in column 1 of the List of Drugs with Extended Expiration Dates. (lot ou lot de fabrication inscrit)

  • SOR/2026-96, s. 24
.

Amended on June 17, 2026

  •  (1) The Minister may add a lot or batch of a drug to column 1 of the List of Drugs with Extended Expiration Dates and a date to column 2 of that list in relation to the lot or batch only if

    • (a) a drug identification number has been assigned to the drug under subsection C.01.014.2(1) and not been cancelled; and

    • (b) the Minister has reasonable grounds to believe that

      • (i) there is a shortage or risk of shortage of the drug,

      • (ii) a shortage of the drug, if it were to occur, could present a risk of injury to human health, and

      • (iii) the lot or batch will comply with the specifications for that drug until at least the date to be added to column 2.

  • (2) In subsection (1), specifications has the same meaning as in section C.02.002.

    SOR/2026-96, s. 24
.

Amended on June 17, 2026

 Sections C.10.017 to C.10.021 apply in respect of a specified lot or batch and its extended expiration date if the following information is also set out in the List of Drugs with Extended Expiration Dates:

  • (a) the drug’s brand name;

  • (b) the drug identification number assigned to the drug;

  • (c) the name of the manufacturer of the drug;

  • (d) the expiration date of the lot or batch; and

  • (e) the date on which the Minister added the lot or batch to that list.

  • SOR/2026-96, s. 24
.

Amended on June 17, 2026

 Despite the definition expiration date in subsection C.01.001(1), a reference to an expiration date in the provisions of this Part — other than paragraph C.10.016(d) — is, in respect of a specified lot or batch, a reference to its extended expiration date.

  • SOR/2026-96, s. 24
.

Amended on June 17, 2026

 Sections C.01.014 and C.08.003 do not apply in respect of a specified lot or batch if its extended expiration date is the only change in respect of the lot or batch that relates to the information previously provided to the Minister in connection with the drug.

  • SOR/2026-96, s. 24
.

Amended on June 17, 2026

  •  (1) Within five days after the day on which a specified lot or batch is added to the List of Drugs with Extended Expiration Dates, the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug shall notify any person who holds an establishment licence and to whom they sold the lot or batch of its extended expiration date.

  • (2) Any person who holds an establishment licence, who has sold a specified lot or batch and who is notified of its extended expiration date shall, within five days after the day on which they are notified, notify any other person to whom they sold the lot or batch of that date.

  • SOR/2026-96, s. 24
.
Loading…